Guiding principles for mechanistic modeling of bispecific antibodies

被引:10
作者
Kareva, Irina [1 ]
Zutshi, Anup [1 ]
Kabilan, Senthil [1 ]
机构
[1] Merck KGaA, EMD Serono, Billerica, MA 01821 USA
关键词
PKPD; Bispecific antibody; Target occupancy; Mechanistic model; Lead compound selection; TARGET COVERAGE; AFFINITY; PHARMACOKINETICS;
D O I
10.1016/j.pbiomolbio.2018.08.011
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
System based pharmacokinetic (PK) models can be used to study and predict the distribution of antibody based drugs into target tissues and assess the pharmacobinding (PB) of the drug to the target and the subsequent pharmacodynamic (PD) changes. In the absence of relevant PD readouts, compounded in cases of novel mechanisms, one can rely on binding between the drug and the target, computed as target occupancy (TO), as a relevant biomarker. This approach assumes that at maximum TO across the dosing interval, the drug-target interaction must demonstrate the intended pharmacology. Such analysis can help set laboratory objectives for protein engineers and chemists and guide them to the appropriate design and binding affinity of the molecule. Analysis of mechanistic models to guide affinity optimization against soluble and membrane-bound targets has been done for monoclonal antibodies (mAbs) (Tiwari et al., The AAPS Journal, 2017). However, comparable understanding of bispecific antibodies (BsAb; drugs with two targets, which are either soluble, membrane-bound, or a combination of the two) is still lacking. We propose to extend the work done by Tiwari et al. (2017) to BsAb. We focus on describing a generic BsAb with two membrane-bound targets, and explore the impact of various parameters on the TO of the BsAb to each target. Performed analysis can guide the optimization of dissociation constant (KD) of the BsAb, and can also help in identifying druggable targets. Proposed model can be modified and tailored to specific biologics as needed. (C) 2018 Elsevier Ltd. All rights reserved.
引用
收藏
页码:59 / 72
页数:14
相关论文
共 18 条
[1]   Bispecific T-Cell Engaging Antibodies for Cancer Therapy [J].
Baeuerle, Patrick A. ;
Reinhardt, Carsten .
CANCER RESEARCH, 2009, 69 (12) :4941-4944
[2]   Quantitative Analysis of Target Coverage and Germinal Center Response by a CXCL13 Neutralizing Antibody in a T-Dependent Mouse Immunization Model [J].
Brodfuehrer, Joanne ;
Rankin, Andrew ;
Edmonds, Jason ;
Keegan, Sean ;
Andreyeva, Tatyana ;
Lawrence-Henderson, Rosemary ;
Ozer, Josef ;
Gao, Huilan ;
Bloom, Laird ;
Boisvert, Angela ;
Lam, Khetemenee ;
Lee, Julie ;
LaBranche, Timothy ;
Syed, Jameel ;
Miao, Wenyan ;
Singh, Pratap .
PHARMACEUTICAL RESEARCH, 2014, 31 (03) :635-648
[3]  
Chames P., 2009, BISPECIFIC ANTIBODIE, P539
[4]   Simulations of site-specific target-mediated pharmacokinetic models for guiding the development of bispecific antibodies [J].
Chudasama, Vaishali L. ;
Zutshi, Anup ;
Singh, Pratap ;
Abraham, Anson K. ;
Mager, Donald E. ;
Harrold, John M. .
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2015, 42 (01) :1-18
[5]   PHYSIOLOGICAL-PARAMETERS IN LABORATORY-ANIMALS AND HUMANS [J].
DAVIES, B ;
MORRIS, T .
PHARMACEUTICAL RESEARCH, 1993, 10 (07) :1093-1095
[6]   Population Pharmacokinetics of Therapeutic Monoclonal Antibodies [J].
Dirks, Nathanael L. ;
Meibohm, Bernd .
CLINICAL PHARMACOKINETICS, 2010, 49 (10) :633-659
[7]   Bispecific antibodies and their applications [J].
Fan, Gaowei ;
Wang, Zujian ;
Hao, Mingju ;
Li, Jinming .
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2015, 8
[8]   KINETIC AND AFFINITY LIMITS ON ANTIBODIES PRODUCED DURING IMMUNE-RESPONSES [J].
FOOTE, J ;
EISEN, HN .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (05) :1254-1256
[9]  
Gibiansky L, 2011, MODELING DRUGS TARGE
[10]   Target-mediated drug disposition model: relationships with indirect response models and application to population PK-PD analysis [J].
Gibiansky, Leonid ;
Gibiansky, Ekaterina .
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2009, 36 (04) :341-351